Houston's 8 biggest charitable donations of 2023 houstonchronicle.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from houstonchronicle.com Daily Mail and Mail on Sunday newspapers.
Health informatics expert earns top honor uta.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uta.edu Daily Mail and Mail on Sunday newspapers.
CLEVELAND (BUSINESS WIRE) Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients.
Athersys, Inc. , a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in. | June 1, 2023
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem® Following Hemorrhagic Trauma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.